Patent assignee · US · COMPANY

LENTIGEN TECHNOLOGY, INC.

38Patents
37Active
38Granted
50Portfolio score

Filing activity: Jun 12, 2016 → Mar 2, 2022

Most-cited patents

PatentTitleAreaCited byStatus
US10442867B2 Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy Chemistry; Metallurgy 6 Active
US10689431B2 Compositions and methods for treating cancer with DuoCARs Chemistry; Metallurgy 6 Active
US10639329B2 Method to treat cancer with engineered T-cells Chemistry; Metallurgy 6 Active
US10183993B2 Compositions and methods for treating cancer with anti-mesothelin immunotherapy Chemistry; Metallurgy 5 Active
US11242389B2 Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy Chemistry; Metallurgy 4 Active
US10550179B2 Compositions and methods for treating cancer with anti-mesothelin immunotherapy Chemistry; Metallurgy 4 Active
US10501539B2 Compositions and methods for treating cancer with anti-CD19 immunotherapy Chemistry; Metallurgy 3 Active
US10426797B2 Compositions and methods for treating cancer with anti-CD33 immunotherapy Chemistry; Metallurgy 3 Active
US10822412B2 Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy Chemistry; Metallurgy 3 Active
US10844128B2 Compositions and methods for treating cancer with anti-CD123 immunotherapy Chemistry; Metallurgy 3 Active
US11208455B2 Compositions and methods for treating cancer with DuoCARs Chemistry; Metallurgy 3 Active
US10421810B2 Chimeric antigen receptors and methods of use Chemistry; Metallurgy 2 Active
US10428141B2 Compositions and methods for treating cancer with anti-ROR1 immunotherapy Chemistry; Metallurgy 2 Active
US10543263B2 Compositions and methods for treating cancer with anti-CD22 immunotherapy Chemistry; Metallurgy 2 Active
US11103533B2 Compositions and methods for treating cancer with anti-CD38 immunotherapy Chemistry; Metallurgy 2 Active
US10894819B2 Compositions and methods for treating HIV/AIDS with immunotherapy Chemistry; Metallurgy 1 Active
US11590169B1 Compositions and methods for treating cancer with anti-CD123 immunotherapy Chemistry; Metallurgy 1 Active
US11453719B2 Compositions and methods for treating cancer with anti-ROR1 immunotherapy Chemistry; Metallurgy 1 Active
US11052112B2 Compositions and methods for treating cancer with anti-BCMA immunotherapy Chemistry; Metallurgy 1 Active
US11680103B2 Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy Chemistry; Metallurgy 0 Active
US11464801B2 Compositions and methods for treating cancer with anti-CD33 immunotherapy Chemistry; Metallurgy 0 Active
US11497770B2 Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy Chemistry; Metallurgy 0 Active
US11970528B2 Compositions and methods for treating cancer with anti-mesothelin immunotherapy Chemistry; Metallurgy 0 Active
US12391958B2 Compositions and methods for treating cancer with anti-CD38 immunotherapy Chemistry; Metallurgy 0 Active
US11878052B2 Compositions and methods for treating cancer with anti-CD22 immunotherapy Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.